Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

Trading Update

29 Apr 2021 07:00

RNS Number : 9817W
Devro PLC
29 April 2021
 

Devro plc

 

Trading Update

 

Devro plc ("Devro" or the "Company"), one of the world's leading manufacturers of collagen products for the food industry, issues the following trading update for the period 1 January 2021 to the current date ahead of its Annual General Meeting today.

Current trading

Q1 2021 edible collagen volumes increased 4.6% compared to the prior year driven by continued good underlying momentum and execution of our growth initiatives. Emerging markets were up 15% led by strong growth in China, South East Asia and Latin America. Mature markets were flat on the prior year, an improvement on the trends seen in 2020. Japan and North America both delivered strong growth but this was offset by lower demand in the UK & Ireland which had benefitted from elevated retail volumes in March 2020 as the pandemic took hold.

Financial position

The Group delivered strong cashflows during Q1, ending the quarter with comparable levels of leverage to 2020 year-end, including the dividend payment made in January 2021.

The Group repaid the US$25 million private placement due on the 19 April 2021 using a combination of available cash resources and RCF drawings. Post this repayment the Group maintains significant liquidity but with a lower average cost of borrowing.

The Group's remaining debt facilities consist of a committed £105 million Revolving Credit Facility (RCF), which expires in 2023, and US$75 million of private placements expiring April 2024 (US$50 million) and 2026 (US$25 million).

Outlook

We are encouraged by the good volume growth performance in Q1 and, whilst we expect this trend to continue we remain mindful of the uncertainties arising from the ongoing COVID-19 pandemic and likely foreign exchange headwinds. As a result, our expectations for 2021 remain unchanged.

ENDS 

Contacts:

 

Devro plc

Rutger Helbing

Chief Executive Officer

Tel: 020 3865 7637

Rohan Cummings

Chief Financial Officer

Tel: 020 3865 7637

 

FTI Consulting

Richard Mountain

Nick Hasell

Tel: 020 3727 1340

 

Dividend: In the Company's announcement on 2 March 2021 of its results for the year ended 31 December 2020, the Board proposed a final dividend of 6.3p per share (the "2020 Final Dividend") to be paid on 1 October 2021, to those shareholders on the register at 20 August 2021, subject to shareholder approval at the Annual General Meeting in April 2021. The Board has subsequently resolved to recommend the payment of the 2020 Final Dividend be brought forward from 1 October 2021 to 20 July 2021, to those shareholders on the register at 11 June 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEFFWAEFSEDL
Date   Source Headline
1st Apr 20221:00 pmRNSBlock Listing Application
31st Mar 20229:57 amRNSDirector/PDMR Shareholding
25th Mar 20223:51 pmRNSAnnual Report & Accounts 2021 & Notice of 2022 AGM
2nd Mar 20227:00 amRNSFULL YEAR RESULTS
21st Jan 20223:17 pmRNSDirector/PDMR Shareholding
20th Jan 20225:39 pmRNSDirector/PDMR Shareholding
19th Jan 20225:23 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSTrading update
16th Dec 202112:14 pmRNSHolding(s) in Company
23rd Nov 20217:00 amRNSTrading Update
2nd Nov 20217:00 amRNSDirectorate Changes
29th Sep 20218:00 amRNSNotice of ESG Seminar
24th Aug 20218:48 amRNSHolding(s) in Company
24th Aug 20218:47 amRNSHolding(s) in Company
12th Aug 20215:55 pmRNSHolding(s) in Company
4th Aug 202111:19 amRNSDirector/PDMR Shareholding
29th Jul 20217:00 amRNSHalf-year Results
27th Jul 20214:57 pmRNSDirector/PDMR Shareholding
4th Jun 20219:05 amRNSDirector Declaration
5th May 20215:15 pmRNSDirector/PDMR Shareholding
4th May 20215:34 pmRNSDirector/PDMR Shareholding
29th Apr 20215:09 pmRNSResult of AGM
29th Apr 20217:00 amRNSTrading Update
15th Apr 20213:14 pmRNSDirector/PDMR Shareholding
13th Apr 20214:53 pmRNSDirector/PDMR Shareholding
26th Mar 20214:47 pmRNS2020 Annual Report and Notice of AGM
10th Mar 20215:04 pmRNSDirector/PDMR Shareholding
5th Mar 20214:45 pmRNSDirector/PDMR Shareholding
2nd Mar 20217:00 amRNSFULL YEAR RESULTS
20th Jan 20219:29 amRNSDirector/PDMR Shareholding
18th Jan 20217:00 amRNSTrading update
18th Dec 20202:12 pmRNSDirector/PDMR Shareholding
24th Nov 20207:00 amRNSTrading Update
22nd Oct 20207:00 amRNSDirectorate Changes
14th Oct 20207:00 amRNSDirectorate Appointment
7th Oct 202010:16 amRNSDirector/PDMR Shareholding
17th Aug 20207:00 amRNSDirector/PDMR Shareholding
29th Jul 20207:01 amRNSDirectorate Change
29th Jul 20207:00 amRNSHALF YEAR RESULTS
30th Jun 20207:00 amRNSAppointment of Corporate Broker
23rd Jun 20209:23 amRNSHolding(s) in Company
12th Jun 20208:27 amRNSDirector/PDMR Shareholding
15th May 202012:02 pmRNSPrice Monitoring Extension
12th May 202011:06 amRNSDirector/PDMR Shareholding
30th Apr 20202:39 pmRNSResult of AGM
29th Apr 20207:00 amRNSDirectorate Appointment
27th Apr 20204:54 pmRNSPublication of Articles of Association
27th Apr 20209:33 amRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSTrading Update
16th Apr 20204:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.